tetano
Editor, Senior Moderator
Vaccine
. 2020 Nov 20;S0264-410X(20)31424-9.
doi: 10.1016/j.vaccine.2020.10.092. Online ahead of print.
Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform
Milan Ganguly[SUP] 1 [/SUP], Leena Yeolekar[SUP] 2 [/SUP], Parikshit Tyagi[SUP] 2 [/SUP], Umesh Sagar[SUP] 2 [/SUP], Swapnil Narale[SUP] 2 [/SUP], Yashodhan Anaspure[SUP] 2 [/SUP], Sham Tupe[SUP] 2 [/SUP], Kuntinath Wadkar[SUP] 2 [/SUP], Nilesh Ingle[SUP] 2 [/SUP], Rajeev Dhere[SUP] 2 [/SUP], Francesco B Scorza[SUP] 3 [/SUP], Kutub Mahmood[SUP] 3 [/SUP]
Affiliations
Abstract
Cell culture based live attenuated influenza vaccines (LAIV) as an alternative to egg-based LAIV have been explored because of lack of easy access to SPF eggs for large scale production. In this study, feasibility of MDCK platform was assessed by including multiple LAIV strains covering both type A (H1 and H3) and type B seasonal strains as well as the candidate pandemic potential strains like A/H5 and A/H7 for the growth in MDCK cells. A risk assessment study was conducted on the cell banks to evaluate safety concerns related to tumorigenicity with a regulatory perspective. Tumorigenic potential of the MDCK cells was evaluated in nude mice (10[SUP]7[/SUP]cells/mouse) model system. The 50% tumor producing dose (TPD[SUB]50[/SUB]) of MDCK cells was studied in SCID mice to determine the amount of cells required for induction of tumors. Further, we conducted an oncogenicity study in three sensitive rodent species as per the requirements specified in the WHO guidelines. We determined TPD[SUB]50[/SUB] value of 1.9 X 10[SUP]4[/SUP] cells/mice through subcutaneous route. Our results suggest that, the intranasal route of administration of the cell culture based LAIV pose minimal to no risk of tumorigenicity associated with the host cells. Also, non-oncogenic nature of MDCK cells was demonstrated. Host cell DNA in the vaccine formulations was < 10 ng/dose which ensures vaccine safety. Production efficiency and consistency were characterized and the observed titer values of the viral harvest and the processed bulk were comparable to the expansion in embryonated eggs. The present study clearly establishes the suitability of MDCK cells as a substrate for the manufacture of a safe and viable LAIV.
Keywords: A/Leningrad/134/17/57(H2N2); B/USSR/60/69; LAIV; MDCK; Manufacturing; Oncogenicity; Tumorigenicity.
. 2020 Nov 20;S0264-410X(20)31424-9.
doi: 10.1016/j.vaccine.2020.10.092. Online ahead of print.
Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform
Milan Ganguly[SUP] 1 [/SUP], Leena Yeolekar[SUP] 2 [/SUP], Parikshit Tyagi[SUP] 2 [/SUP], Umesh Sagar[SUP] 2 [/SUP], Swapnil Narale[SUP] 2 [/SUP], Yashodhan Anaspure[SUP] 2 [/SUP], Sham Tupe[SUP] 2 [/SUP], Kuntinath Wadkar[SUP] 2 [/SUP], Nilesh Ingle[SUP] 2 [/SUP], Rajeev Dhere[SUP] 2 [/SUP], Francesco B Scorza[SUP] 3 [/SUP], Kutub Mahmood[SUP] 3 [/SUP]
Affiliations
- PMID: 33229107
- DOI: 10.1016/j.vaccine.2020.10.092
Abstract
Cell culture based live attenuated influenza vaccines (LAIV) as an alternative to egg-based LAIV have been explored because of lack of easy access to SPF eggs for large scale production. In this study, feasibility of MDCK platform was assessed by including multiple LAIV strains covering both type A (H1 and H3) and type B seasonal strains as well as the candidate pandemic potential strains like A/H5 and A/H7 for the growth in MDCK cells. A risk assessment study was conducted on the cell banks to evaluate safety concerns related to tumorigenicity with a regulatory perspective. Tumorigenic potential of the MDCK cells was evaluated in nude mice (10[SUP]7[/SUP]cells/mouse) model system. The 50% tumor producing dose (TPD[SUB]50[/SUB]) of MDCK cells was studied in SCID mice to determine the amount of cells required for induction of tumors. Further, we conducted an oncogenicity study in three sensitive rodent species as per the requirements specified in the WHO guidelines. We determined TPD[SUB]50[/SUB] value of 1.9 X 10[SUP]4[/SUP] cells/mice through subcutaneous route. Our results suggest that, the intranasal route of administration of the cell culture based LAIV pose minimal to no risk of tumorigenicity associated with the host cells. Also, non-oncogenic nature of MDCK cells was demonstrated. Host cell DNA in the vaccine formulations was < 10 ng/dose which ensures vaccine safety. Production efficiency and consistency were characterized and the observed titer values of the viral harvest and the processed bulk were comparable to the expansion in embryonated eggs. The present study clearly establishes the suitability of MDCK cells as a substrate for the manufacture of a safe and viable LAIV.
Keywords: A/Leningrad/134/17/57(H2N2); B/USSR/60/69; LAIV; MDCK; Manufacturing; Oncogenicity; Tumorigenicity.